Positron-emission Tomography for Hepatocellular Carcinoma: Current Status and Future Prospects

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2019 Sep 19

PMID 31528094

Citations 32

Authors

Ren-Cai Lu

Bo She

Wen-Tao Gao

Yun-Hai Ji

Dong-Dong Xu

Quan-Shi Wang

Shao-Bo Wang

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer mortality worldwide. Various imaging modalities provide important information about HCC for its clinical management. Since positron-emission tomography (PET) or PET-computed tomography was introduced to the oncologic setting, it has played crucial roles in detecting, distinguishing, accurately staging, and evaluating local, residual, and recurrent HCC. PET imaging visualizes tissue metabolic information that is closely associated with treatment. Dynamic PET imaging and dual-tracer have emerged as complementary techniques that aid in various aspects of HCC diagnosis. The advent of new radiotracers and the development of immuno-PET and PET-magnetic resonance imaging have improved the ability to detect lesions and have made great progress in treatment surveillance. The current PET diagnostic capabilities for HCC and the supplementary techniques are reviewed herein.

Citing Articles

Prostate-Specific Membrane Antigen (PSMA) PET/CT in the Detection and Diagnosis of Hepatocellular Carcinoma (HCC): A Systematic Review and Meta-Analysis.

Hannah N, Yu C, Nedumannil L, Haridy J, Kong G, Boussioutas A Cancers (Basel). 2024; 16(22).

PMID: 39594820 PMC: 11592426. DOI: 10.3390/cancers16223865.

Recent Trends in Liver Cancer: Epidemiology, Risk Factors, and Diagnostic Techniques.

Kale S, Karande G, Gudur A, Garud A, Patil M, Patil S Cureus. 2024; 16(10):e72239.

PMID: 39583507 PMC: 11584332. DOI: 10.7759/cureus.72239.

Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.

Bitar R, Salem R, Finn R, Greten T, Goldberg S, Chapiro J Radiology. 2024; 313(2):e232875.

PMID: 39560477 PMC: 11605110. DOI: 10.1148/radiol.232875.

Development of quantitative PET/MR imaging for measurements of hepatic portal vein input function: a phantom study.

Chalampalakis Z, Ortner M, Almuttairi M, Bauer M, Tamm E, Schmidt A EJNMMI Phys. 2024; 11(1):90.

PMID: 39489802 PMC: 11532313. DOI: 10.1186/s40658-024-00694-4.

High-Grade Hepatic Spindle Cell Carcinoma as a Cause of Diffuse Right Hepatic Lobe Hypermetabolism Identified With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET/CT) Imaging.

Al-Adhami D, Al-Shatti M, Alrabi K, Haidar M, Al-Ibraheem A Cureus. 2024; 16(9):e68793.

PMID: 39371758 PMC: 11456283. DOI: 10.7759/cureus.68793.

References

Hoffend J, Mier W, Schuhmacher J, Schmidt K, Dimitrakopoulou-Strauss A, Strauss L . Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nucl Med Biol. 2005; 32(3):287-92. DOI: 10.1016/j.nucmedbio.2005.01.002. View

Ametamey S, Honer M, Schubiger P . Molecular imaging with PET. Chem Rev. 2008; 108(5):1501-16. DOI: 10.1021/cr0782426. View

Park J, Kim J, Kim S, Kang K, Park K, Choi J . A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008; 49(12):1912-21. DOI: 10.2967/jnumed.108.055087. View

Hwang K, Choi D, Lee S, Lee M, Choe W . Evaluation of patients with hepatocellular carcinomas using [(11)C]acetate and [(18)F]FDG PET/CT: A preliminary study. Appl Radiat Isot. 2009; 67(7-8):1195-8. DOI: 10.1016/j.apradiso.2009.02.011. View

Song W, Nielson B, Banks K, Bradley Y . Normal organ standard uptake values in carbon-11 acetate PET imaging. Nucl Med Commun. 2009; 30(6):462-5. DOI: 10.1097/MNM.0b013e32832aa7ce. View

Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M . P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol. 2009; 34(5):1303-12. View

Huo L, Wu Z, Zhuang H, Fu Z, Dang Y . Dual time point C-11 acetate PET imaging can potentially distinguish focal nodular hyperplasia from primary hepatocellular carcinoma. Clin Nucl Med. 2010; 34(12):874-7. DOI: 10.1097/RLU.0b013e3181bed06e. View

Talbot J, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F . Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010; 51(11):1699-706. DOI: 10.2967/jnumed.110.075507. View

Ho M, Kim H . Glypican-3: a new target for cancer immunotherapy. Eur J Cancer. 2010; 47(3):333-8. PMC: 3031711. DOI: 10.1016/j.ejca.2010.10.024. View

10.

Krasikova R, Kuznetsova O, Fedorova O, Belokon Y, Maleev V, Mu L . 4-[18F]fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization. J Med Chem. 2010; 54(1):406-10. DOI: 10.1021/jm101068q. View

11.

Kolthammer J, Corn D, Tenley N, Wu C, Tian H, Wang Y . PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging. 2011; 38(7):1248-56. DOI: 10.1007/s00259-011-1743-y. View

12.

Bernstine H, Braun M, Yefremov N, Lamash Y, Carmi R, Stern D . FDG PET/CT early dynamic blood flow and late standardized uptake value determination in hepatocellular carcinoma. Radiology. 2011; 260(2):503-10. DOI: 10.1148/radiol.11102350. View

13.

Kim J, Seong J, Yun M, Lee I, Yoon H, Cho H . Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2011; 82(3):1172-8. DOI: 10.1016/j.ijrobp.2010.11.076. View

14.

Anis M, Irshad A . Imaging of hepatocellular carcinoma: practical guide to differential diagnosis. Clin Liver Dis. 2011; 15(2):335-52, vii-x. DOI: 10.1016/j.cld.2011.03.014. View

15.

Sung T, Lee S, Lee J, Lee Y, Lee A, Hwang D . Hepatocellular carcinoma eats medullary thyroid carcinoma, a case of tumor-in-tumor metastasis. Endocr J. 2011; 58(9):801-5. DOI: 10.1507/endocrj.ej11-0052. View

16.

Sacks A, Peller P, Surasi D, Chatburn L, Mercier G, Subramaniam R . Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol. 2011; 197(2):W260-5. DOI: 10.2214/AJR.11.6995. View

17.

Kornberg A, Kupper B, Tannapfel A, Buchler P, Krause B, Witt U . Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver Transpl. 2011; 18(1):53-61. DOI: 10.1002/lt.22416. View

18.

Lin C, Chen J, Liang J, Lin C, Jeng L, Kao C . 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol. 2011; 81(9):2417-22. DOI: 10.1016/j.ejrad.2011.08.004. View

19.

Wu H, Wang Q, Li B, Li H, Zhou W, Wang Q . F-18 FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med. 2011; 36(12):1092-7. DOI: 10.1097/RLU.0b013e3182335df4. View

20.

Pan J, Dong M, Ouyang X . A hepatoid adenocarcinoma of the stomach with liver metastasis mimicking hepatocellular carcinoma detected by F-18 FDG PET/CT imaging. Clin Nucl Med. 2011; 36(12):1137-9. DOI: 10.1097/RLU.0b013e3182335ef9. View